BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 5
• 6
• 7
• 8
• 9
• 11
• 12
• 13
• 14
• 15
• 16
• 19
• 20
• 21
• 22
• 27
• 28
• 29
• 30

• BioMidwest

  ISA Scientific Announces Completion Of Corporate Rebrand To Ananda Scientific In Preparation For Leadership In Global CBD Sales

  December 21, 2016

   · 

  3 min read
• IntelliPharmaCeutics Announces Issuance Of U.S. And Canadian Patents Covering Aspects Of Its PODRAS Overdose Technology

  December 21, 2016

   · 

  10 min read
• Drug Development

  Inovio Pharma’s Zika Vaccine Generates Robust Immune Responses In First Human Study

  December 21, 2016

   · 

  4 min read
• Drug Development

  Janssen Biotech Submits Two Applications To FDA Seeking Approval Of SIMPONI ARIA (Golimumab) For The Treatment Of Active Psoriatic Arthritis And Active Ankylosing Spondylitis

  December 21, 2016

   · 

  12 min read
• Drug Development

  AzurRx BioPharma Announces First Three Patients Included In Phase Ila Study With MS1819-SD For Endocrine Pancreatic Insufficiency

  December 21, 2016

   · 

  5 min read
• Policy

  Intrinsic Therapeutics Announces The Filing Of PMA Application For Its Barricaid Anular Closure Device For Lumbar Discectomy Patients

  December 21, 2016

   · 

  4 min read
• Policy

  Advanced Accelerator Applications Receives Complete Response Letter From FDA For Lutathera, An Investigational Treatment For Neuroendocrine Tumors

  December 21, 2016

   · 

  6 min read
• Deals

  SYGNIS Acquires Profitable US Life Sciences Tools Company C.B.S. Scientific For U.S. $0.9 Million In Cash And Shares

  December 21, 2016

   · 

  2 min read
• Drug Development

  Unexpected Clinical Results Cause Hansa Medical to Terminate Phase II With IdeS in Acquired TTP

  December 21, 2016

   · 

  2 min read
• Drug Development

  After Failed Phase III, Auven to Terminate the KIACTA Program

  December 21, 2016

   · 

  6 min read